The standing regulatory base and the 2026 developments behind iFeed's weekly signals — the in-scope references across bioanalytical, bioequivalence, clinical trials and quality. Primary-sourced, and maintained alongside the weekly stream.
FDA's authoritative list of approved drugs with therapeutic-equivalence (AB/BX) codes, reference listed drugs (RLD), reference standards (RS), and patent/exclusivity data underpinning ANDA/Hatch-Waxman filings.
Defines the RLD/RS a generic must be shown bioequivalent to and its substitutability rating.
The EU's core BE guideline specifying design, conduct, and 80.00-125.00% acceptance criteria for IR dosage forms; still in force but progressively superseded by ICH M13A with an EMA implementation-considerations paper published Feb 2025.
Still the reference framework for EU BE submissions and the baseline the ICH M13 series is replacing.
OGD's recommended dissolution apparatus, media, and specifications for products lacking a USP method, used with the f2 similarity factor (similar when f2 >= 50) to support BE and biowaiver decisions.
The go-to source for the dissolution methodology and f2 comparisons at the heart of biowaivers and complex-generic BE.
FDA's searchable repository of product-specific bioequivalence recommendations telling ANDA sponsors the study design, endpoints, and dissolution/PK/PD approach expected for each reference drug; new and revised PSGs are issued quarterly.
The single most-used reference for designing a compliant BE program for any given generic product.
WHO's multisource (generic) interchangeability and biowaiver requirements (TRS 1052 Annex 8; BCS biowaiver list TRS 1044 Annex 11; ICH M9 adopted) governing BE for prequalified generics.
The BE/biowaiver standard for generics targeting WHO-PQ and low- and middle-income-country markets.
Post-Brexit MHRA requirements that BE/PK/TE comparator products be representative of the UK reference product, alongside the International Recognition Procedure that can leverage FDA/EMA approvals for UK generics.
Defines the UK-specific comparator-sourcing rule generics must meet for British marketing authorisations.
Harmonised criteria for waiving in vivo BE studies for BCS Class I and III immediate-release oral products based on solubility, permeability, and comparative in vitro dissolution; superseded FDA's 2017 BCS biowaiver guidance.
The route by which generics avoid costly in vivo BE studies entirely for qualifying molecules.
FDA's overarching guidance on general BA/BE principles, PK metrics (Cmax, AUC), fed/fasted design, and reference-product handling for drugs submitted in NDAs/INDs.
Sets the baseline PK and study-design conventions that all BE work builds on.
The user-fee program (in effect 1 Oct 2022-30 Sep 2027) funding ANDA review, with performance goals covering PSG issuance, pre-ANDA meetings for complex products, and assessment timelines.
Sets the review timelines, fees, and complex-generic support commitments that shape every generic development plan.
The first harmonised ICH guideline on BE study design and data analysis for IR solid oral dosage forms; effective 25 January 2025 and superseding applicable parts of the EMA BE guideline for non-replicate designs.
Now the globally-aligned rulebook for single-strength IR oral BE studies, replacing divergent regional rules.
FDA-industry negotiations to reauthorize the generic-drug user-fee program before GDUFA III expires 30 Sep 2027; kicked off at a July 2025 public meeting with commitment-letter development running through 2026.
Will reset ANDA review timelines, fees, and complex-generic/BE program funding for 2028 onward.
FDA's Q1 2026 batch of new and revised draft product-specific BE guidances announcing recommended study approaches for additional reference products.
Each batch tells generic developers exactly how FDA expects BE to be demonstrated for newly-covered molecules.
Finalized (from the Oct 2022 draft) guidance on Q3 sameness/similarity/difference characterization of semisolid and liquid topical generics and how Q3 results affect the additional evidence needed to demonstrate BE.
Enables a comparative-characterization route to BE for topical/semisolid complex generics, reducing clinical-endpoint studies.
FDA approved the first generics of the SGLT2 inhibitor dapagliflozin for type-2 diabetes and heart-failure indications, granting approval to multiple ANDA applicants.
A high-volume, high-value first generic whose approval hinged on a standard oral PK BE demonstration.
In May 2026 FDA revised several product-specific guidances to cut the expensive comparative clinical-endpoint studies previously needed for generic inhalation products, favouring in vitro / PK weight-of-evidence BE.
Materially lowers the BE evidentiary burden and cost for developing generic inhalers.
FDA's Q2 2026 batch of new/revised draft PSGs (comments due 21 Jul 2026), the routine GDUFA III mechanism for publishing BE recommendations for specific generic products.
Newly issued/revised PSGs directly reset the BE study expectations for the listed products.
FDA's continuously-updated 2026 table of first-time generic approvals, including Bortezomib, Mirabegron ER for suspension, Rifaximin tablet, Ferric Citrate, and multiple Brivaracetam products, each requiring a successful BE demonstration.
The running record of which reference products newly face BE-based generic competition in 2026.
FDA finalized its statistical-BE guidance, replacing the February 2001 version and finalizing the December 2022 draft; it covers average BE, log-transformation, replicate/adaptive designs, NTI and highly-variable (scaled-average BE) drugs, outliers, and encourages model-based BE.
The current statistical rulebook for analyzing BE data, including reference-scaled BE for highly variable drugs and NTI approaches.
Companion final guidance (finalizing the Aug 2021 revised draft) on how to conduct PK-endpoint BE studies for ANDAs, ANDA amendments, and supplements and meet FD&C Act BE requirements.
The definitive ANDA-facing manual for how PK BE studies must be designed and reported.
The second guideline in the ICH M13 series, harmonising when a BE study can be waived for additional strengths given in vivo BE at one strength; reached Step 2b consultation in 2025 with Step 4 finalization expected in 2026.
Will standardise strength-biowaiver criteria, letting generics avoid repeat BE studies across a dosage series.
FDA's annual GDUFA science workshop (8-9 Jun 2026) presenting new BE approaches and regulatory research for complex generics, including inhalation, transdermal, and long-acting injectable/implant BE.
Signals FDA's near-term BE-methodology priorities and emerging alternative BE approaches for complex products.
Guideline establishing the Development Safety Update Report as the common annual safety report standard for investigational drugs across ICH regions (FDA guidance Aug 2011).
Defines the core annual clinical-trial safety reporting obligation sponsors must meet during development.
General principles for planning and designing multi-regional clinical trials (ICH 2017; FDA/EU 2018), including use of a single global protocol and assessment of consistency of treatment effect across regions.
Underpins global simultaneous development and how CT professionals justify pooling multi-region data for marketing approval.
Addendum to ICH E11 (adopted 2017; FDA guidance 2018) updating pediatric drug-development approaches including extrapolation, modelling/simulation and integration of pediatric planning.
Foundational reference for ethical, efficient pediatric trial design and pediatric investigation plans.
FDA final guidance (2 Dec 2019) on adaptive designs for drug and biologic trials, covering pre-specification, type I error control, and Bayesian and simulation-based complex designs.
The standing US reference for defensible adaptive trial designs, now being harmonized by draft ICH E20.
Addendum on estimands and sensitivity analysis (ICH Step 4 2019; FDA guidance May 2021) giving a structured framework linking trial objectives to how intercurrent events are handled in the analysis.
Estimands are now expected in protocols and SAPs, directly affecting trial design and the regulatory acceptability of efficacy claims.
Revised general-considerations guideline (adopted 6 Oct 2021) that embeds quality-by-design and identification of factors 'critical to quality' across the clinical study lifecycle.
Sets the QbD foundation that E6(R3) operationalizes, shaping how CT teams plan fit-for-purpose studies.
Regulation (EU) No 536/2014 with CTIS as the single EU submission portal; transition of legacy Directive trials completed on 31 Jan 2025, making the CTR fully operative across the EU/EEA.
The governing legal framework and IT system for any interventional trial conducted in the EU/EEA.
EMA/HMA/EC recommendation paper (13 Dec 2022), a harmonized non-binding EU view on eConsent, home trial procedures, IMP delivery, monitoring and sponsor/investigator responsibilities in DCTs.
The main EU reference bridging DCT practice with the CTR until formal methodology guidance matures.
FDA pilot offering selected rare-disease and gene-therapy sponsors frequent, informal FDA communication to accelerate the design and conduct of their clinical development programs.
A rare-disease trial-acceleration mechanism relevant to sponsors seeking intensive early FDA engagement.
FDA final guidance (22 Dec 2023) on digital health technologies for remote data acquisition, covering DHT selection, verification/validation, device considerations and data integrity.
Governs the sensors, wearables and apps that enable decentralized and remote data capture in modern trials.
EMA's revised CTIS transparency rules (applying to trials submitted from 18 Jun 2024) simplify publication, remove the up-to-seven-year deferral mechanism and rely on structured data fields to speed public access.
Changes what trial data becomes public and when, affecting sponsor disclosure planning across the EU.
FDA draft guidance (26 Jun 2024) implementing FDORA's requirement for Diversity Action Plans with enrollment goals by age, sex and race/ethnicity; later removed from FDA's website after the Jan 2025 executive order, leaving final policy uncertain.
Represents the contested but statutorily-rooted enrollment-diversity obligation CT sponsors must continue to track.
New guideline (ICH Step 4 21 Aug 2024; FDA guidance Dec 2024) providing a systematic framework for pediatric extrapolation, treating extrapolation as a continuum and addressing safety extrapolation.
Lets sponsors reduce or waive some pediatric studies by leveraging adult/other data, reshaping pediatric trial planning.
FDA final guidance (18 Sep 2024), mandated by FDORA, addressing remote trial activities, telehealth visits, roles of local providers, and IMP handling in decentralized clinical trials.
The definitive US playbook for DCTs, directly affecting protocol logistics, monitoring and participant access.
The HMA-EC-EMA ACT EU initiative, whose 3rd workplan (adopted Dec 2024) sets 2025-2026 deliverables to streamline CTR implementation, harmonize methodology guidance, and improve multi-stakeholder engagement.
Signals the direction of EU trial-process reform and the upcoming methodology guidances sponsors will need to follow.
The modernized GCP guideline (Principles + Annex 1) adopted by ICH on 6 Jan 2025, applied in the EU from 23 Jul 2025 and issued as FDA final guidance on 9 Sep 2025; introduces a risk-based, quality-by-design, technology-agnostic framework replacing E6(R2).
E6(R3) is the most consequential GCP overhaul in three decades and now governs how all interventional trials are designed, conducted and overseen.
FDA draft guidance (Jan 2025) implementing FDORA authority on when a confirmatory trial is 'underway' (enrollment begun, credible completion timeline) at or after accelerated approval.
Directly affects timing and planning of confirmatory trials for accelerated-approval programs.
FDA's first draft guidance (7 Jan 2025) proposing a risk-based credibility-assessment framework for AI models used to support regulatory decisions across the nonclinical, clinical, and post-marketing drug lifecycle.
First FDA framework for validating AI/ML used in trial data generation, analysis and safety evaluation.
FDA CDER/CBER process (announced 3 Sep 2025) allowing approval of therapies for ultra-rare, single-gene diseases (fewer than 1,000 US patients) on one adequate and well-controlled trial plus robust confirmatory evidence.
Offers a predictable evidentiary pathway that reshapes trial design and endpoints for ultra-rare genetic diseases.
ICH E20 draft guideline reached Step 2b on 25 Jun 2025 and entered consultation (FDA draft Sep 2025), harmonizing FDA/EMA thinking on pre-specification, simulation and Bayesian/enrichment adaptive designs; finalization expected in 2026.
Will become the global standard for confirmatory adaptive trials, so CT statisticians and designers are tracking it now.
FDA final guidance (18 Dec 2025) that drops the expectation of securing identifiable individual-level data access for RWD sources and judges RWE on fitness-for-purpose; FDA signaled it intends a similar change for drugs and biologics.
A substantive loosening of FDA RWE standards likely to extend to drug trials, external controls and label expansion.
Pilot (launched Jun 2025) granting nontransferable vouchers with enhanced engagement, rolling review and a 1-2 month review target; the first new molecular entity (orforglipron) was approved 1 Apr 2026 and FDA held a public hearing on 4 Jun 2026.
A fast-track review pathway that materially alters submission strategy, rolling-review planning and timelines for priority products.
FDA draft guidance (25 Feb 2026, comments to 27 Apr 2026) describing a 'plausible mechanism' framework to generate substantial evidence for individualized genome-editing and RNA therapies where randomized trials are not feasible.
Enables single-application, master-protocol development of n-of-few individualized therapies for ultra-rare genetic conditions.
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (SI 2025/538), signed in 2025 with a 12-month implementation, came into force on 28 Apr 2026, introducing combined MHRA/ethics review, mandatory trial registration and results reporting, and 'modification' terminology.
The biggest UK trials-law overhaul in two decades, changing approvals, transparency and recruitment timelines for UK studies.
FDA revised draft guidance (24 Jun 2026) replacing the 2023 draft and adding sections on basket, umbrella and platform trials across therapeutic areas, with design, analysis and submission recommendations.
Updates FDA expectations for the platform/basket trials increasingly central to modern drug development.
FDA revised draft guidance (24 Jun 2026) clarifying how one adequate and well-controlled trial plus confirmatory evidence can meet the substantial-evidence standard, signaling a single-pivotal-trial default and early FDA engagement.
Potentially the biggest shift in US efficacy evidence standards, directly changing pivotal-trial strategy.
The core US CGMP regulations setting minimum requirements for manufacturing, processing, packing and holding of finished drug products.
The predicate rules FDA inspects and enforces against; nearly every drug-quality warning letter cites Part 211.
The harmonised GMP guidance for APIs, providing the quality-system and manufacturing-control foundation on which ICH Q10 builds.
Defines GMP expectations for API makers worldwide and underpins global inspection of the drug-substance supply chain.
The harmonised model for a lifecycle pharmaceutical quality system (PQS), built on CAPA, change management, process/product monitoring and management review.
The backbone PQS model referenced throughout modern GMP and the new Annex 11 / QMSR risk framing.
The current in-force EU GMP annex on computerised systems (validation, audit trails, electronic signatures, data controls), pending the major 2025-drafted revision.
The standing EU benchmark for computerised-system compliance that industry must still meet until the revision is finalised.
The generic QMS standard built on the process approach, PDCA cycle and risk-based thinking, applicable across sectors and foundational to sector-specific QMS standards.
The baseline QMS grammar (risk-based thinking, process approach) underlying pharma quality-system design and supplier qualification.
The international medical-device QMS standard, now incorporated by reference into FDA's QMSR (21 CFR 820) and the global harmonisation target for device quality systems.
As of Feb 2026 it is effectively US law for device makers and the reference for risk-based device quality systems.
The UK regulator's cross-GxP data-integrity guidance codifying ALCOA+ and data-governance expectations for paper, electronic and hybrid systems.
A foundational, widely cited interpretation of data-integrity expectations spanning manufacturing, QC, pharmacovigilance and clinical data.
Provides tools (Established Conditions, post-approval change management protocols) for managing post-approval CMC changes through the quality system to enable innovation and reduce drug shortages.
Governs how manufacturing changes are categorised and managed post-approval - a core quality-system and change-control lever.
The 63-page PIC/S data-integrity guidance (in force 1 Jul 2021) covering data governance, the data lifecycle, paper and computerised systems, used by inspectorates across 50+ authorities.
The most detailed harmonised data-integrity expectation set that inspectors apply globally.
The July 2022 second edition of the globally used risk-based framework for validating GxP computerised systems, updated for service providers, Agile/software tooling and new appendices on AI/ML, cloud, blockchain and CSA.
The de-facto industry method for computerised-system validation and the practical bridge to FDA's CSA approach.
The 2023 revision of the QRM guideline addressing subjectivity, the formality of risk work, supply/availability risk, and risk-based decision-making, including use of digitalisation and emerging technologies.
The reference framework for risk-based quality decisions that regulators now expect embedded across the pharmaceutical quality system.
The first harmonised guidance for continuous manufacturing of drug substances and products, covering control strategy, state of control, process dynamics and lifecycle management (Step 4 Nov 2022; adoption 2023).
Sets quality and control expectations for CM as manufacturers modernise away from batch processing.
The 2022 overhaul (in force 25 Aug 2023; section 8.123 from Aug 2024) mandates a holistic Contamination Control Strategy (CCS), quality risk management, and modern barrier technologies (RABS/isolators) for sterile production.
Defines current sterile-manufacturing and contamination-control expectations that now dominate EU/PIC-S inspections.
The world's first certifiable AI management system standard (Dec 2023) for governing responsible development and use of AI, addressing bias, transparency, human oversight and continual improvement.
The emerging governance backbone pharma will use to make GxP AI auditable and to meet Annex 22 and EU AI Act expectations.
EMA's finalised reflection paper setting risk-based expectations for AI/ML across drug discovery, development, manufacturing and pharmacovigilance.
The EU regulatory foundation for GxP AI that underpins the January 2026 EMA-FDA principles and forthcoming AI guidance.
A complete rewrite (from ~5 to ~19 pages) opened for consultation 7 Jul-7 Oct 2025, adding cybersecurity, cloud/outsourced IT, stronger audit-trail and e-signature controls and ICH Q10 integration; final publication expected mid-2026.
The most consequential overhaul of EU computerised-system GMP in 14 years, reshaping validation, data integrity and supplier oversight.
FDA finalised its CSA guidance on 24 Sep 2025 (updated 3 Feb 2026 to align with QMSR/ISO 13485), promoting a risk-based, least-burdensome approach to assuring production and quality-system software.
Officially shifts industry from exhaustive CSV toward risk-based CSA - a major change in how GxP computerised systems are validated.
Technical amendments finalising conforming changes to Part 820 and related device regulations ahead of the QMSR's 2 Feb 2026 effective date.
Confirms the final regulatory text device makers must comply with as the QMSR takes effect.
On 11 Feb 2026 FDA opened a third cohort (up to nine establishments; requests due 13 Apr 2026) of its voluntary CDER QMM prototype assessment, evaluating quality-management practices beyond baseline CGMP.
FDA's clearest 2026 push toward proactive quality-culture maturity and more resilient drug supply, beyond pass/fail inspection.
Q1 2026 saw a cluster of CDER warning letters citing data-integrity and CGMP failures - e.g., Fareva Morton Grove (3 Mar 2026): an uncontrolled water system, failure to contemporaneously record complete microbiological data, and discarded test plates - several linked to Import Alert 66-40 detention.
Concrete 2026 evidence that data integrity and quality-unit oversight remain the dominant CGMP enforcement risk, especially at overseas and contract-lab sites.
A first-of-its-kind draft (published 9 Mar 2026, comments close 8 May 2026) recommending manufacturers submit a concise, root-cause-focused 483 response within 15 business days, warning that late responses may not be considered before inspection classification.
Directly changes how quality units must respond to inspection findings, with enforcement consequences for weak responses.
CGMP requirement that computerised laboratory/manufacturing systems be validated, calibrated, access-controlled and backed up, with data secured from alteration, erasure or loss.
The specific CGMP hook FDA cites for CDS/HPLC data-integrity deficiencies in labs.
US regulation establishing criteria for trustworthy electronic records and signatures, audit trails, access controls, and validation of computerised systems such as chromatography data systems (CDS).
The binding US rule governing electronic bioanalytical/CDS records and e-signatures.
EMA's guideline defining validation of bioanalytical methods generating quantitative concentration data for PK/TK, adopted July 2011 and effective February 2012.
The still-referenced EU baseline for bioanalytical validation that underpinned and now complements ICH M10.
Harmonised compendial LAL-based bacterial endotoxins test with gel-clot, turbidimetric and chromogenic techniques and maximum-valid-dilution calculation.
The standing US compendial endotoxin method against which recombinant-reagent alternatives are benchmarked.
FDA guidance (finalized 2015) on establishing and validating analytical procedures and methods submitted in NDAs/ANDAs/BLAs, including validation characteristics and system suitability.
A standing FDA reference for analytical method validation applied across pharmaceutical QC/analytical labs.
USP general chapter defining the DQ/IQ/OQ/PQ framework for qualifying analytical instruments (HPLC, LC-MS) as the foundation of the data-quality triangle.
Sets the baseline instrument-qualification expectation underpinning valid chromatographic data.
MHRA's cross-GxP data-integrity guidance defining ALCOA+, the data lifecycle, and controls for paper, hybrid and electronic systems including audit-trail review and blank-form control.
A foundational data-integrity framework widely applied and inspected in bioanalytical and QC laboratories.
FDA's finalized 2018 guidance on developing, validating and applying chromatographic and ligand-binding bioanalytical methods for drugs, metabolites, therapeutic proteins and biomarkers in biological matrices.
Remains FDA's cornerstone BMV reference alongside ICH M10 and defines expectations audited in regulated bioanalytical labs.
FDA's final Q&A guidance clarifying CGMP data-integrity expectations, ALCOA, audit trails, access controls, backups and 21 CFR 211.68, for laboratory and manufacturing records.
The primary FDA statement of data-integrity expectations that drives the majority of laboratory warning-letter findings.
Ph. Eur. general chapter 2.6.32 introduced rFC as a validated animal-free alternative to LAL for bacterial endotoxin testing, with deployment guidance in the revised 5.1.10 (published 2020, effective January 2021).
Establishes rFC as a Ph. Eur.-recognised endotoxin method for EU QC/microbiology laboratories.
Harmonised general chapter defining apparatus, procedures and acceptance stages for dissolution testing of oral dosage forms.
A core compendial performance test routinely run and validated in pharmaceutical QC labs.
USP general chapter on validating compendial analytical procedures, being revised to align with the ICH Q2(R2)/Q14 lifecycle and fitness-for-purpose approach.
Defines how labs validate and demonstrate fitness-for-purpose of compendial test methods.
WHO's 2021 data-integrity guideline (replacing TRS 996 Annex 5) requiring an ALCOA+ data-governance system embedded in the quality system, with QRM and good-documentation examples.
The global WHO benchmark for data governance applied to laboratory and manufacturing data lifecycles.
The 63-page PIC/S inspector guidance (in force July 2021) harmonising data-integrity expectations across GMP/GDP, covering data governance, computerised systems, audit trails and risk-based DI assessment.
The reference document inspectors use worldwide when assessing laboratory data integrity.
The globally harmonised ICH guideline (Step 4, May 2022) setting requirements for validating chromatographic (LC-MS) and ligand-binding bioanalytical assays and analysing study samples, covering calibration, QCs, selectivity, carryover, stability and incurred sample reanalysis (ISR).
The single most important standing reference governing bioanalytical method validation across FDA/EMA/PMDA-regulated PK/TK studies.
Revised ICH guideline (adopted Nov 2023; FDA final March 2024) on validating analytical procedures, now extended to multivariate/spectroscopic techniques (NIR, Raman, NMR, MS).
Defines the validation characteristics (specificity, accuracy, precision, range) for analytical/QC methods used in regulated labs.
New ICH guideline (adopted Nov 2023; FDA final March 2024) describing enhanced, science- and risk-based development and lifecycle management of analytical procedures.
Establishes the analytical-procedure lifecycle/QbD framework increasingly expected for method development and change control.
April 2024 draft guidance giving data-integrity recommendations for the clinical and bioanalytical portions of BA/BE and nonclinical studies submitted to FDA (docket FDA-2024-D-1245).
The most BA-specific FDA data-integrity guidance, directly targeting the reliability of bioanalytical study data.
PDG-harmonised general chapter specifying chromatographic system-suitability parameters and allowable adjustments; a revision to System Sensitivity and Peak Symmetry became official 1 May 2025.
The controlling compendial standard for HPLC/GC system suitability and method adjustments in QC and bioanalytical labs.
New USP general chapter (early adoption Nov 2024; official May 2025) permitting animal-free endotoxin testing using recombinant Factor C (rFC) and recombinant cascade reagent (rCR) as alternatives to <85>.
Enables validated non-animal endotoxin testing for QC/microbiology labs and codifies rFC/rCR acceptance.
From 1 January 2026 the rabbit pyrogen test (general chapter 2.6.8) is deleted from the Ph. Eur.; recombinant Factor C is fully integrated as one of seven methods in 2.6.14 (Bacterial endotoxins), with method choice governed by 5.1.13.
A landmark framework change forcing EU labs to transition endotoxin/pyrogen testing to validated non-animal methods (rFC, MAT).
FDA cited significant CGMP violations at this API/finished-drug facility, including unexplained laboratory/production discrepancies and an inability to account for rejected material intended for the US market.
A representative Q1-2026 laboratory data-integrity/CGMP enforcement action against a drug manufacturer.
FDA cited this contract lab for falsifying nonclinical study reports, altering final reports to misidentify Vedic as the testing facility and its personnel as study directors when studies were run elsewhere.
A 2026 GLP/bioanalytical data-integrity enforcement action striking at CRO study-data reliability.